Portland Global Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$815K Hold
886
0.09% 77
2025
Q4
$952K Buy
886
+6
+0.7% +$5.74K 0.1% 75
2025
Q3
$671K Buy
880
+130
+17% +$96.7K 0.08% 83
2025
Q2
$585K Buy
750
+6
+0.8% +$4.66K 0.07% 90
2025
Q1
$614K Buy
744
+12
+2% +$9.98K 0.08% 79
2024
Q4
$565K Buy
732
+4
+0.5% +$3.31K 0.07% 87
2024
Q3
$645K Buy
728
+13
+2% +$11.7K 0.08% 86
2024
Q2
$647K Sell
715
-129
-15% -$103K 0.09% 84
2024
Q1
$657K Hold
844
0.09% 82
2023
Q4
$492K Hold
844
0.07% 86
2023
Q3
$453K Sell
844
-100
-11% -$51.5K 0.08% 87
2023
Q2
$443K Hold
944
0.07% 92
2023
Q1
$324K Sell
944
-325
-26% -$110K 0.06% 109
2022
Q4
$464K Sell
1,269
-82
-6% -$29.1K 0.09% 95
2022
Q3
$437K Sell
1,351
-75
-5% -$23.8K 0.09% 94
2022
Q2
$462K Hold
1,426
0.09% 94
2022
Q1
$408K Hold
1,426
0.07% 103
2021
Q4
$394K Hold
1,426
0.07% 107
2021
Q3
$329K Hold
1,426
0.06% 124
2021
Q2
$327K Buy
1,426
+94
+7% +$18.9K 0.06% 122
2021
Q1
$249K Buy
+1,332
New +$261K 0.05% 131

Other funds holding LLY

Portland Global Advisors's LLY Position: Q1 2026 in Review

Portland Global Advisors held its Eli Lilly (LLY) position steady in Q1 2026 at 886 shares worth $815K. The position accounts for 0.09% of the portfolio, ranked #77.

Portland Global Advisors first reported a position in LLY in Q1 2021 and has held it in 21 quarters since. The position peaked at $952K in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Portland Global Advisors held 886 shares of Eli Lilly worth $815K as of Q1 2026.
  • Portland Global Advisors left its Eli Lilly share count unchanged in Q1 2026.
  • Eli Lilly made up 0.09% of Portland Global Advisors's portfolio in Q1 2026, its #77 holding.
  • Portland Global Advisors first reported a position in Eli Lilly in Q1 2021 and has held it in 21 quarters since.
  • Portland Global Advisors's Eli Lilly position peaked at $952K in Q4 2025.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Portland Global Advisors's 13F filing for Q1 2026, filed 11 May 2026.